Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) is a member of the tumor necrosis factor cytokine superfamily, which has emerged as a promising anticancer drug, because it induces apoptosis in cancer cells with minimal cytotoxicity toward normal cells [1–4]. Here, TNFSF10 is linked to cancer.